Fredag 14 Mars | 13:28:17 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-11-12 08:00 Kvartalsrapport 2025-Q3
2025-08-13 08:00 Kvartalsrapport 2025-Q2
2025-05-15 N/A X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2025-05-14 N/A Årsstämma
2025-05-14 08:00 Kvartalsrapport 2025-Q1
2025-02-26 - Bokslutskommuniké 2024
2025-01-20 - Extra Bolagsstämma 2025
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-04-05 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-12-20 - Extra Bolagsstämma 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-07-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Årsstämma
2023-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 - Årsstämma
2022-05-13 - Kvartalsrapport 2022-Q1
2022-04-08 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-12-19 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-13 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-07-25 - Extra Bolagsstämma 2018
2018-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 - Årsstämma
2018-05-08 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-22 - Kvartalsrapport 2017-Q2
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-04-22 - Bokslutskommuniké 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-09-21 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2025-02-26 08:00:00

QUARTER 4, OCTOBER – DECEMBER 2024

  • Net revenue decreased by 63 percent to SEK 971k (2 657k).
  • EBITDA improved by 41 percent to SEK -3 180k (-5 403k).
  • EBIT/Operating result deteriorate by 6 percent to SEK -9 241k (-8 683k).

INTERIM PERIOD, JANUARY – DECEMBER 2024

  • Net revenue decreased by 34 percent to SEK 2 890k (4 354k).
  • EBITDA improved by 21 percent to SEK -17 593k (-22 366k).
  • EBIT/Operating result improved by 5 percent to SEK -34 714k (-36 635k).

KEY EVENTS DURING THE QUARTER

  • Simris Group major owner and chairman Steven Schapera passed away after complications after surgery. Jonathan Royce, an existing board member, has assumed the role of chairman of the board.
  • Simris Group announced that payments from the previously announced and agreed loan facility, established by the recently deceased major shareholder and chairman Steven Schapera’s company, may be delayed. The Simris board is reviewing other financing options in case the payments are further delayed.
  • Simris Group resolved a share issue, repayment of convertible debentures, prolongation of loan agreements, entering into and to call for a general meeting to resolve to enter into new loan agreements.

KEY EVENTS AFTER THE END OF THE QUARTER

  • Simris Group held an extraordinary general meeting on 20 January 2025. The general meeting resolved on entering into loan agreements from board and management on total €140 000.

CEO UPDATE
Our mission is to treat cancer with greater precision than chemotherapy or radiotherapy. We will do this using our ground-breaking IP protected ADC payload technology, via strategic alliances with experienced drug developers. Every day we move closer towards this pivotal goal.
In reflection writing this update for our Simris Group, it is with sadness we all remember our previous Chairman Steven Schapera’s passing and his vision. However, over this last quarter, we have galvanized our energy, financial status, focus & determination to continue the mission and vision of delivering novel and sustainable ADC payloads to advance the war against cancer.

We continued to push forward our collaborations in a number of fronts. Through our work with an independent global Pharma company, we obtained the first set of in-vitro study data with our novel payloads conjugated to a monoclonal antibody. This work demonstrated promising results for our monomer microcystins—a favorable safety profile and a comparable effectiveness versus leading commercialized ADC constructs. We also continue dialogues with other pharma companies.

We initiated discussion with the world-renowned Cancer Research Centre to build a research programme for multiple myeloma cancer treatment to screen our most advanced microcystin payloads in specific ADC conjugates.

We continue to obtain approval for our patents in several key regions around the world for the next generation of bioconjugate innovation and manufacturing technology, specifically as these inventions relate to ADC payloads. Continuing to build our strong, defensible and protected IP position for our payload platform is a high priority for Simris. Our patent library protects our unique position to offer specifically optimizable payloads which are ready to conjugate for further ADC development and commercialization.

Our unique science and value to cancer precision medicine was recognized in our recent key publication in the American Chemical Society’s Journal of Natural Products (also awarded Editor’s Choice) that describes the outstanding work on “Derivatization of Mycrocystins can increase target inhibition while reducing cellular update”.
https://pubs.acs.org/doi/10.1021/acs.jnatprod.4c00688

Our groundbreaking science is leading the way in ADC payload safety and efficacy for oncology.

The first phase of the Proof of Concept (POC) for our Peptide Drug Conjugate (PDC) research programme with the New Zealand Universities has yielded some interesting early data during a fertility and fecundity (mating) study cycle over a 53 day period. The next steps of this POC is currently being initiated.

With respect our Hammenhög Facility in Southern Sweden, we have thoroughly explored opportunities for industrial and academic collaborations to maximize the future potential for the facility.

Our laser focused plan to continue to grow our expertise in conjugation of ADC payloads and applications with specific microcystin science is leading to fruitful data for further optimization which in turn will attract stronger interest in partnerships/collaborations to achieve in-vivo data.

The report is published on Simris Groups website:
https://simrisgroup.com/financial-information/financial-reports/